Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/180762
Title: | A cluster-randomized trial of hydroxychloroquine for prevention of Covid-19 |
Author: | Mitjà Villar, Oriol Corbacho-Monné, Marc Ubals, Maria Alemany Ortiz, Andrea Suñer Navarro, Clara Tebé, Cristian Tobias, Aurelio Peñafiel, Judith Ballana, Ester Pérez, Carla A. Admella, Pol Riera-Martí, Núria Laporte, Pep Mitjà, Jordi Clua, Mireia Bertran, Laia Sarquella, Maria Gavilán, Sergi Ara, Jordi Argimón Pallás, José M. Cuatrecasas, Gabriel Cañadas, Paz Elizalde Torrent, Aleix Fabregat, Robert Farré Albaladejo, Magí Forcada, Anna Flores Mateo, Gemma López, Cristina Muntada, Esteve Nadal, Núria Narejos, Silvia Nieto, Aroa Prat, Núria Puig, Jordi Quiñones, Carles Ramírez-Viaplana, Ferran Reyes Urueña, Juliana Maria Riveira-Muñoz, Eva Ruiz, Lidia Sanz, Sergi |
Keywords: | Agents antiinfecciosos Ús terapèutic COVID-19 Anti-infective agents Therapeutic use COVID-19 |
Issue Date: | 4-Feb-2021 |
Publisher: | Massachusetts Medical Society |
Abstract: | Background: current strategies for preventing severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection are limited to nonpharmacologic interventions. Hydroxychloroquine has been proposed as a postexposure therapy to prevent coronavirus disease 2019 (Covid-19), but definitive evidence is lacking. Methods: we conducted an open-label, cluster-randomized trial involving asymptomatic contacts of patients with polymerase-chain-reaction (PCR)-confirmed Covid-19 in Catalonia, Spain. We randomly assigned clusters of contacts to the hydroxychloroquine group (which received the drug at a dose of 800 mg once, followed by 400 mg daily for 6 days) or to the usual-care group (which received no specific therapy). The primary outcome was PCR-confirmed, symptomatic Covid-19 within 14 days. The secondary outcome was SARS-CoV-2 infection, defined by symptoms compatible with Covid-19 or a positive PCR test regardless of symptoms. Adverse events were assessed for up to 28 days. Results: the analysis included 2314 healthy contacts of 672 index case patients with Covid-19 who were identified between March 17 and April 28, 2020. A total of 1116 contacts were randomly assigned to receive hydroxychloroquine and 1198 to receive usual care. Results were similar in the hydroxychloroquine and usual-care groups with respect to the incidence of PCR-confirmed, symptomatic Covid-19 (5.7% and 6.2%, respectively; risk ratio, 0.86 [95% confidence interval, 0.52 to 1.42]). In addition, hydroxychloroquine was not associated with a lower incidence of SARS-CoV-2 transmission than usual care (18.7% and 17.8%, respectively). The incidence of adverse events was higher in the hydroxychloroquine group than in the usual-care group (56.1% vs. 5.9%), but no treatment-related serious adverse events were reported. Conclusions: postexposure therapy with hydroxychloroquine did not prevent SARS-CoV-2 infection or symptomatic Covid-19 in healthy persons exposed to a PCR-positive case patient. (Funded by the crowdfunding campaign YoMeCorono and others; BCN-PEP-CoV2 ClinicalTrials.gov number, NCT04304053.). |
Note: | Reproducció del document publicat a: https://doi.org/10.1056/NEJMoa2021801 |
It is part of: | New England Journal of Medicine, 2021, vol. 384, num. 5, p. 417-427 |
URI: | http://hdl.handle.net/2445/180762 |
Related resource: | https://doi.org/10.1056/NEJMoa2021801 |
ISSN: | 0028-4793 |
Appears in Collections: | Articles publicats en revistes (Ciències Clíniques) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
715041.pdf | 543.57 kB | Adobe PDF | View/Open |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.